CNCR vs. GNOM

Last updated Jun 6, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and GNOM (Global X Genomics & Biotechnology ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while GNOM tracks the Solactive Genomics Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.50%/yr for GNOM.

Performance

CNCR vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

GNOM

• 1D: -4.23%
• 1M: 3.36%
• YTD: 6.84%
• 6M: 4.93%
• 1Y: 51.76%
• 3Y*: -1.47%
• 5Y*: -10.36%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. GNOM - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
GNOM Global X Genomics & Biotechnology ETF	5.28%

CNCR vs. GNOM - Sectors Allocation Comparison

Sectors	CNCR	GNOM
Healthcare	96.6%	99.6%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	0.4%
Utilities	-	-

Return for Risk

CNCR vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM

GNOM Risk / Return Rank: 57
GNOM Sharpe Ratio Rank: 59
GNOM Sortino Ratio Rank: 61
GNOM Omega Ratio Rank: 53
GNOM Calmar Ratio Rank: 60
GNOM Martin Ratio Rank: 51

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	GNOM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.93	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.31	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.09	—

Drawdowns

CNCR vs. GNOM - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for CNCR and GNOM.

Drawdown Indicators

	CNCR	GNOM	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-75.00%	+75.00%
Max Drawdown (1Y) Largest decline over 1 year	—	-18.17%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-46.47%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-72.29%	—
Current Drawdown Current decline from peak	0.00%	-55.85%	+55.85%
Average Drawdown Average peak-to-trough decline	0.00%	-40.57%	+40.57%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	6.31%	—

Volatility

Volatility by Period

	CNCR	GNOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.57%	—
Volatility (6M) Calculated over the trailing 6-month period	—	19.99%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	27.01%	-27.01%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	33.65%	-33.65%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	34.21%	-34.21%

CNCR vs. GNOM - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than GNOM's 0.50% expense ratio.

Dividends

CNCR vs. GNOM - Dividend Comparison

CNCR has not paid dividends to shareholders, while GNOM's dividend yield for the trailing twelve months is around 1.29%.

Position	TTM	2025	2024	2023	2022	2021	2020
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GNOM Global X Genomics & Biotechnology ETF	1.29%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%

Frequently Asked Questions

Which ETF is better, CNCR or GNOM?

On fees, GNOM is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or GNOM?

GNOM is cheaper with a 0.50% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or GNOM?

GNOM has the higher dividend yield at 1.29%, compared with 0.00% for CNCR.

What is the main difference between CNCR and GNOM?

CNCR tracks Loncar Cancer Immunotherapy Index, while GNOM tracks Solactive Genomics Index. They also come from different issuers: Exchange Traded Concepts and Global X. Their fees differ too: 0.79% for CNCR and 0.50% for GNOM.